Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib in ALK-positive NSCLC identified via Blood-based Assays
KCT0004234Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Started Jun 2020; status: terminated.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0004234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004234.